Switch to:
GuruFocus has detected 2 Warning Signs with Valeant Pharmaceuticals International Inc $VRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Valeant Pharmaceuticals International Inc (NYSE:VRX)
Research & Development
$414 Mil (TTM As of Mar. 2017)

This is the expense the company spent on research and development. Valeant Pharmaceuticals International Inc's research and development for the three months ended in Mar. 2017 was $96 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2017 was $414 Mil.


Definition

This is the expense the company spent on research and development.

Valeant Pharmaceuticals International Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2017 was 124.3 (Jun. 2016 ) + 100.8 (Sep. 2016 ) + 92.8 (Dec. 2016 ) + 96 (Mar. 2017 ) = $414 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
Research & Development 118931071586679157246334421

Valeant Pharmaceuticals International Inc Quarterly Data

Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16Mar17
Research & Development 595681102961031241019396
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK